Caplyta vs Vyvanse
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Caplyta | US Vyvanse | |
|---|---|---|
| Generic name | lumateperone | lisdexamfetamine |
| Drug class | Atypical Antipsychotic | CNS Stimulant |
| Treats | Schizophrenia, bipolar depression | ADHD, binge eating disorder |
| Category | Mental Health | Mental Health |
| Manufacturer | Intra-Cellular Therapies | Takeda |
| Year approved | 2019 | 2007 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $130M | $70M |
| Common side effects | Drowsiness, Dry mouth, Dizziness, Nausea | Decreased appetite, Insomnia, Dry mouth, Increased heart rate |
Frequently asked questions
Is Caplyta or Vyvanse better?
Neither is universally "better." Caplyta (lumateperone) and Vyvanse (lisdexamfetamine) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Caplyta and Vyvanse?
Caplyta is a Atypical Antipsychotic made by Intra-Cellular Therapies, while Vyvanse is a CNS Stimulant made by Takeda. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Caplyta has the larger estimated TV advertising budget of the two.